In 1984, Stanley Feldman wrote this about suxamethonium: "In spite of its many disadvantages and some potential lethal dangers, it remains the only drug presently available that will produce a rapid, complete neuromuscular block of about 5-10 minutes duration." Twenty years later, the same remains true and suxamethonium remains on the anaesthetic machine despite the myriad of new muscle relaxants available.
Whilst developing gallamine, Bovet and his co-workers studied a number of other substances with muscle relaxant properties. Among these was succinylcholine iodide (suxamethonium) which was shown to be a short acting muscle relaxant. In 1951 Low and Tammelin synthesized succinylcholine iodide in a crystalline form which was free from impurities.
Pharmacological testing of the drug in the laboratory and the operat ing theatre was undertaken by Dardel and Thesleff at the Karolinska Institute. They described the depolarizing nature of the block seen with succinylcholine which had previously been seen with decamethonium and large doses of acetylcholine. Succinylcholine was shown to be short acting and metabolized by esterases. Complete muscle relaxation occurred within sixty seconds after a brief period of muscle twitching. Since curare and other available muscle relaxants all caused a degree of hypotension, this was a sideeffect they were anxious to exclude. Animal tests demonstrated no drop in blood pressure despite giving several thousand times the paralysing dose. They did not demonstrate any histamine release and animal testing with intravenous infusions demonstrated that this was a drug with great potential as an infusion. The duration of action had already been shown to be prolonged with cholinesterase inhibitors such as prostigmine and physostigmine, so the researchers did not feel this was of suffi cient duration to be clinically useful.
Clinical tests began in 1951 and the preliminary series consisted of 132 patients. "It was administered together with intravenous barbiturates, nitrous oxide, ether, cyclopropane and, in a few instances, with insuffi cient spinal anaesthesia." Muscle relaxation was still only used when it was thought indicated. It was not necessarily maintained throughout the case and often not with the aim of suspending respiration. "Succinylcholine was given when muscle relaxation was desired, such as for intubation or relaxation of the muscles of the abdomen or extremities, if necessary until respiratory arrest occurred." If prolonged muscle relaxation was required, repeated doses were given every three minutes, but as their experience grew they began experimenting with infusions. "Later we found it simpler to give succinylcholine in an intravenous drip, in a concentration of 1-2mg. per ml … This resulted in relaxation of the peripheral muscles without depression of respiration." They found succinylcholine to be particularly benefi cial for short procedures, such as reduction of fractures, and for closing the abdomen at the end of laparotomies.
In Britain, Cyril Scurr began experimenting with another depolarizing relaxant created by Bovet-suxethonium. He initially found it most useful for electroconvulsive therapy and peritoneal closure. He switched to suxamethonium as it soon became more readily available and began using it as an infusion. "We soon appreciated the drawbacks of bradycardia from repeat doses, and the sequel of muscle after-pains ..."
These side-effects were being widely recognized as suxamethonium rapidly became popular. Isolated reports of pro-longed apnoea were also appearing in the literature, and in 1956, Francis Foldes and his colleagues reviewed many of these reports and their likely causes. "For a while the frequency of appearance of those reports was such that it seemed unlikely that this valuable agent would weather the storm and keep its place among the clinically employable muscle relaxants." They quickly concluded that there was probably more than one cause for the problem, "... not a single pathological entity, but rather a syndrome which may be caused by a variety of factors". Among the causes they listed low pseudocholinesterase levels, general debility, factors related to general anaesthesia and pathological changes to the neuromuscular junction. They felt strongly that these could be avoided. "If succinylcholine is used correctly and respirations are assisted rather than controlled, succinylcholine apnea is a preventable complication."
The problem of dual block was also elucidated at this time. H. J. Brennan from the Manchester Royal Infi rmary reported a case of prolonged suxamethonium apnoea which responded to neostigmine. He noted that there had been a few other such cases reported in the literature. He concluded "when a patient is given fairly large doses of suxamethonium chloride by drip infusion, this drug and possibly the succinylmonochlorine formed as an interval product in its normal hydrolysis, change their mode of action and become antidepolarizing agents … if ever this condition is encountered an adequate dose of neostigmine should be administered".
The more sinister complication of hyperkalaemia in burns and spinal patients was not reported until the 1960s. This is not really surprising given the fact that many of these patients are extremely unwell and cardiac arrest is not unexpected. Suxamethonium was implicated in some of these cardiac arrests but it was diffi cult to prove the association. Tolmie and colleagues took advantage of the fact that one of their burns patients required several anaesthetics and used the same anaesthetic on each occasion. The fi rst ten were uneventful but at each of the subsequent anaesthetics the patient arrested shortly after induction and ECG changes were consistent with hyperkalaemia. In conclusion they stated "The idea of an effl ux of potassium ion associated with succinylcholine administration is not new and has been shown in cat hind limbs by Paton ... it would seem more advisable to use gallamine to facilitate intubation on the post-burn patient ..." Tetrahydroaminacrine (THA) was fi rst investigated as a useful drug in 1949 by Shaw and Bentley. It was initially studied as an analeptic to stimulate the arousal and restore respiration. It is an anticholinesterase and therefore prolongs the action of suxamethonium. Whilst there are other drugs with this property, none produced a desirable duration of action. THA prolonged the action of suxamethomium from about three minutes to about twelve. Accordingly it found a place as an adjunct to suxamethonium infusions where it was shown to decrease the incidence of muscle pains, which were high with this technique, decrease the risk of dual block and provide a more consistent level of relaxation. THA was also used as a stimulant to arouse patients with respiratory depression after general anaesthesia. The advent of non-depolarizing muscle relaxants of shorter duration led to a decrease in the use of the suxamethonium/THA technique in the 1980s. Ampoules of suxamethonium (Scoline) and tetrahydroaminacrine (Tacrine, THA).
